Cantor Fitzgerald upgraded Regeneron (REGN) to Overweight from Neutral with a price target of $695, down from $800, as the analyst took over coverage of the stock.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron CRL for Eylea extension not surprising, says Oppenheimer
- Regeneron receives complete response letter for Eylea extended dosing
- Regeneron announces FDA accepted Priority Review sBLA for EYLEA HD
- Regeneron, Sanofi announce FDA approval of Dupixent for CSU
- Regeneron announces FDA accepted Priority Review sBLA for EYELEA HD